CompletedNCT04047472
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
PHASE3 · 397 planned enrolment
- Countries listed
- 1
- Registry update
- December 9, 2024
Registry Intervention View
Aflibercept 2 mg
Trial registrations containing the exact intervention label Aflibercept 2 mg.
Exact registry label · Not reported
4 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
4 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT04005352
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
PHASE3 · 734 planned enrolment
- Countries listed
- 20
- Registry update
- October 9, 2024
CompletedNCT03386474
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
PHASE3 · 151 planned enrolment
- Countries listed
- 2
- Registry update
- January 5, 2021
CompletedNCT02257632
Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
PHASE4 · 41 planned enrolment
- Countries listed
- 1
- Registry update
- May 7, 2019